Skip Navigation
Oklahoma State University

ANSYS and Dr. Feng’s research group partner to Derive the Next-Generation Computational Lung Aerosol Dynamics Model

Dr. Yu Feng’s research group announced the formation of an academic partnership with ANSYS Inc. (Pittsburg, PA), to extend lung aerosol dynamics modeling to the cell level. As a result of the new partnership, ANSYS will provide Dr. Yu Feng’s group licenses of the entire ANSYS suite of mechanical, computational fluid dynamics and multiphysics software. Dr. Yu Feng’s lab, i.e., Computational Biofluidics and Biomechanics Laboratory (CBBL), will make contributions to the medical world and human life by providing well-posed solutions to patient-specific pulmonary health problems using multi-scale modeling techniques realized on ANSYS Mechanical/CFD platforms. By reconstructing a subject-specific whole lung model covering the entire lung conducting zone (from mouth to Generation 17), Dr. Feng’s research group will be able to use Computational fluid-particle dynamics (CFPD) and Physiologically Based Pharmacokinetic (PBPK) models to calculate the transport, deposition, translocation, and clearance of inhaled toxic or therapeutic aerosols in the pulmonary route and systemic regions. Using the new multi-scale CFPD-PBPK model, researchers will be able to provide high-resolution data and perform parametric sensitivity studies for lung geometric and operational factors that affect aerosol uptakes/clearance in the human bodies under realistic breathing patterns.

Dr. Thierry Marchal, the Global Industry Director of Healthcare, Construction & Consumer Products of ANSYS, said that “We would be honored to add Dr. Yu Feng’s research group in the network, together with other world-class respiratory academic partners.We would be very keen to introduce Dr. Yu Feng to discuss the computational pulmonary aerosol research he is leading as a global reference.“

Dr. Yu Feng said, “We are grateful to ANSYS for the academic partnership grant. Through this collaboration, our research group will be able to utilize ANSYS suite to develop a novel multiscale CFPD-PBPK model, which will serve as a non-invasive health effect assessment tool for multiple biomedical applications, i.e., drug inhaler design optimization for effective and targeted drug deliveries.”